RESEARCH TRIANGLE PARK, N.C. -- Icagen, Inc. (NASDAQ: ICGN) today announced that the Company has recently met the seventy five percent point of enrollment in the Company's pivotal Phase III trial of ICA-17043 for the chronic oral treatment of sickle cell disease, with 225 of the total expected study population...
WINNIPEG, MANITOBA, Sep 20, 2007 CCNMatthews via COMTEX -- Medicure Inc. (TSX:MPH)(AMEX:MCU), a cardiovascular focused biopharmaceutical company, today announced the completion of enrollment of 3,000 patients in its MEND-CABG II trial. This pivotal WINNIPEG, MANITOBA, Sep 20, 2007 CCNMatthews via COMTEX -- Medicure Inc. (TSX:MPH)(AMEX:MCU),...
WINNIPEG, MANITOBA, Nov 17, 2006 CCNMatthews via COMTEX -- Medicure Inc. (TSX:MPH)(AMEX:MCU), a cardiovascular focused biopharmaceutical company, today announced it has commenced enrollment in the MEND-CABG II study. This single confirmatory Phase WINNIPEG, MANITOBA, Nov 17, 2006 CCNMatthews via COMTEX -- Medicure Inc. (TSX:MPH)(AMEX:MCU),...
INDIANAPOLIS -- Guidant Corporation (NYSE:GDT) today announced that the company has begun enrollment in its SPIRIT III drug eluting stent clinical trial.
REDWOOD CITY, Calif. -- A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced that it expects to have initial data from its Phase 3 clinical trial with APF530 in the second half of 2007, and plans to file a New Drug Application NDA with the U.S. Food and Drug...
Date: January 16, 2007 Refer to: Joedy Isert Eli Lilly and Company 317-276-5592 office 317-997-8544 cell Jo-ann Straat Daiichi Sankyo USA 973-359-2602 office Shigemichi Kondo ...
- Amendment Results in Accelerated Payments of $8.5 Million - MONTVALE, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that it has amended its nicotinic alpha-7 receptor agonist agreement with Roche to expand the Phase 2 development program for R3487/MEM 3454 in cognitive impairment...
BOSTON & PERTH, Australia -- Global drug delivery company, pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FSE: PSI) today reported the interim three-month safety and efficacy results from the first human pharmacokinetic(1) PK study of Medidur[TM] FA, in patients with Diabetic Macular Edema DME. This Phase II study is designed...
Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced positive data following the successful completion of the Phase I/II clinical trial for CTCE-9908, the Company's anti-cancer drug candidate. The primary objective of this...
An Independent Clinical Study Previously Has Demonstrated 100% of Responding Patients Achieving and Sustaining Significant Disease Free Survival Benefit Measured in Terms of Years WORCESTER, Mass. -- Biovest International, Inc. (OTCBB:BVTI) ("Biovest" or the "Company"), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced today...
An Independent Clinical Study Previously Has Demonstrated 100% of Responding Patients Achieving and Sustaining Significant Disease Free Survival Benefit Measured in Terms of Years TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that its majority owned subsidiary, Biovest International, Inc. (OTCBB:BVTI) ("Biovest"), has secured...
EDMONTON, ALBERTA, Dec 5, 2007 Marketwire via COMTEX -- ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for certain solid tumours, announced today that preliminary analysis of results from the two Phase...
ViRexx Medical Corp. (TSX: VIR) (AMEX: REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for certain solid tumours, announced today that preliminary analysis of results from the two Phase III clinical trials of OvaRex® MAb for the treatment of advanced...
LEXINGTON, Mass. -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended September 30, 2007. Synta reported a net loss of $14.9 million or...
Patients treated with STA-4783 experienced median overall survival of 12 months Benefit appears to extend to those patients who failed treatment with initial chemotherapy and crossed over to receive STA-4783 LEXINGTON, Mass. -- Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on...
DALLAS -- American Food Co., Inc. (OTC: AFHD) has been rated "Speculative Buy" with a target price of $.40 by Beacon Equity Research Analyst, Lisa Springer, CFA. The full report is available at http://www.BeaconEquityResearch.com Anyone interested in receiving alerts regarding American Food Co.,...
Key Milestone for First-in-Man DNA Vaccine Clinical Trial Using Inovio's Electroporation DNA Delivery Technology SAN DIEGO -- Inovio Biomedical Corp. (AMEX: INO), focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced...
RESEARCH TRIANGLE PARK, N.C. -- Icagen, Inc. (NASDAQ: ICGN) reported today its financial results for the fourth quarter and year ended December 31, 2006. For the fourth quarter of 2006, the Company reported revenues of $1.7 million and a net loss of $6.2 million. For the year...
EDMONTON, Alberta, January 22 /PRNewswire/ -- Toronto Stock Exchange Symbol: MS - On track to announce interim data in mid-2008 - EDMONTON, Alberta, January 22 /PRNewswire/ -- BioMS Medical Corp (TSX: MS), a leading...
Articles 2007-01-22
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors
